Semaglutide
Who holds supplier records for Semaglutide? 61 organisations hold a current record for Semaglutide: an active US FDA Type II Drug Master File. Recorded organisation countries for current records: China (35), India (7), Belgium (1), United States (1) and 1 other country (1); not recorded for 16.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Semaglutide: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/semaglutide
Reading the evidence
- 61 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- Most recorded organisations are in China
35 of the 45 current records with a recorded country list China. Organisation country is not necessarily the manufacturing site.
- 12 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Semaglutide expires 17 Feb 2041. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (61)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Semaglutide. Country is the organisation's recorded country, not necessarily the manufacturing site.
- FUJIAN GENOHOPE BIOTECH LTDChina Company GMP cert on recordActive DMF 39522, 40957, 39932 +1 · latest filing Sept 2025
- SHENZHEN JYMED TECHNOLOGY CO LTDChinaActive DMF 41170, 36009, 41090 +1 · latest filing Feb 2026
- ZHEJIANG PEPTITES BIOTECH CO LTDChinaActive DMF 42288, 35712, 43245 +1 · latest filing Dec 2025
- Hybio Pharmaceutical Co., Ltd.China Company GMP cert on recordActive DMF 44328, 40319, 38443 · latest filing Jul 2026
- SINOPEP-ALLSINO BIOPHARMACEUTICAL CO LTDChinaActive DMF 43275, 42796, 36273 · latest filing Dec 2025
- PolypeptideBelgiumActive DMF 36101, 38177 · latest filing Aug 2023
- Yangzhou Aurisco Pharmaceutical Co.,Ltd.ChinaActive DMF 38479, 42525 · latest filing Sept 2025
- ALP PHARM BEIJING CO LTDActive DMF 35875 · latest filing Apr 2021
- AMBIO INCUnited StatesActive DMF 36015 · latest filing Aug 2021
- ANHUI POLY PHARM CO LTDChinaActive DMF 41314 · latest filing Feb 2025
- ANHUI TAIENKANG PHARMACEUTICAL CO LTDChinaActive DMF 41023 · latest filing Dec 2024
- APICORE LLC (A WHOLLY OWNED SUB OF RK PHARMA INC)Active DMF 40124 · latest filing Jun 2024
- ASYMCHEM LIFE SCIENCE TIANJIN CO LTDChina Company GMP cert on recordActive DMF 39091 · latest filing Nov 2023
- AURO PEPTIDES LTDActive DMF 42442 · latest filing Mar 2026
- BACHEM AGCompany GMP cert on recordActive DMF 37594 · latest filing Mar 2023
- Beijing Ql Biopharmaceutical Co., Ltd.ChinaActive DMF 38480 · latest filing Aug 2023
- Biocon LimitedIndiaActive DMF 40714 · latest filing Dec 2024
- CHANGZHOU PHARMACEUTICAL FACTORYChina Company GMP cert on recordActive DMF 42883 · latest filing Oct 2025
- CHENGDU BRILLIANT BIOPHARMACEUTICAL CO LTDChinaActive DMF 43182 · latest filing Jan 2026
- CHINESE PEPTIDE COChinaActive DMF 39104 · latest filing Nov 2023
- CHONGQING CHEN'AN BIOPHARMACEUTICAL CO LTDActive DMF 38798 · latest filing Sept 2023
- Chongqing Sintaho Pharmaceutical Co., Ltd.ChinaActive DMF 42038 · latest filing Jun 2025
- Dr. Reddy's Laboratories Ltd.India Company GMP cert on recordActive DMF 36036 · latest filing Aug 2021
- El-Peptido (Shanghai) Biopharmaceutical Co., LtdChinaActive DMF 43425 · latest filing Dec 2025
- FDC LimitedIndia Company GMP cert on recordActive DMF 43785 · latest filing Mar 2026
- GUANGDONG ZETAPHARMAX CO LTDChinaActive DMF 40212 · latest filing Jul 2024
- HANGZHOU GO TOP PEPTIDE BIOTECH CO LTDChinaActive DMF 39930 · latest filing May 2024
- HANGZHOU THINHEAL PHARMA-TECH CO LTDChinaActive DMF 39902 · latest filing Jun 2024
- HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL CO LTDChinaActive DMF 38507 · latest filing Jul 2023
- HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL JIANGDONG CO LTDActive DMF 40713 · latest filing Jan 2025
- HARBIN JIXIANGLONG BIOTECH CO LTDActive DMF 39609 · latest filing Feb 2024
- Hetero Drugs LimitedIndia Company GMP cert on recordActive DMF 44229 · latest filing Jul 2026
- HUISHENG BIOPHARMACEUTICAL CO LTDActive DMF 39495 · latest filing Mar 2024
- JILIN QIJIAN BIO-PHARMACEUTICAL CO LTDChinaActive DMF 44246 · latest filing Jun 2026
- LEPU PHARMACEUTICAL CO LTDActive DMF 44008 · latest filing Jun 2026
- MSN LIFE SCIENCES PRIVATE LIMITEDIndia Company GMP cert on recordActive DMF 38729 · latest filing Sept 2023
- NANJING CELLNUO BIOPHARMACEUTICAL CO LTDChinaActive DMF 39847 · latest filing Jun 2024
- NANJING HANXIN PHARMACEUTICAL TECHNOLOGY CO LTDChinaActive DMF 39209 · latest filing Sept 2024
- NINGBO KUNPENG BIOTECH CO LTDChinaActive DMF 40069 · latest filing Jun 2024
- NINGXIA LANBOSI CHEMISTRY TECHNOLOGY CO LTDActive DMF 41594 · latest filing Mar 2025
- Piramal Pharma LimitedIndia Company GMP cert on recordActive DMF 43801 · latest filing Mar 2026
- REALI TIDE BIOLOGICAL TECHNOLOGY (WEIHAI) CO LTDChinaActive DMF 41187 · latest filing Mar 2025
- SHANXI TONGDA PHARMACEUTICAL CO LTDActive DMF 40973 · latest filing Feb 2025
- SHENZHEN READLINE BIOTECH CO LTDChinaActive DMF 39791 · latest filing Apr 2024
- SICHUAN DUORUI BIOPHARMACEUTICAL CO LTDActive DMF 43251 · latest filing Dec 2025
- Sichuan Jisheng Biopharmaceutical Co.,LtdChinaActive DMF 41576 · latest filing Mar 2025
- SICHUAN QISHENG BIOMEDICAL TECHNOLOGY CO LTDChinaActive DMF 40496 · latest filing Sept 2024
- Sun Pharmaceutical Industries LimitedIndia Company GMP cert on recordActive DMF 36345 · latest filing Oct 2021
- Suzhou Lixin Pharmaceutical Co., Ltd.ChinaActive DMF 41945 · latest filing Jun 2025
- SUZHOU MOTIF BIOTECH CO LTDActive DMF 41860 · latest filing May 2025
- SUZHOU RYWAY BIOTECH CO LTDActive DMF 40989 · latest filing Dec 2024
- SUZHOU TIANMA PHARMA GROUP TIANJI BIO-PHARMACEUTICAL CO LTDChinaActive DMF 38213 · latest filing Mar 2023
- TAPI NL BVNetherlandsActive DMF 42108 · latest filing Dec 2025
- VIRTU PHARMAKO (ZHEJIANG) CO LTDChinaActive DMF 44039 · latest filing Apr 2026
- WUHAN MORE BIOTECHNOLOGY CO LTDActive DMF 39115 · latest filing Nov 2023
- XIUSHI BIOPHARMA (NANTONG) CO LTDChinaActive DMF 41460 · latest filing Mar 2025
- XIUSHI BIOPHARMA(RUDONG)ChinaActive DMF 44827 · latest filing Sept 2026
- Zhejiang Huahai Pharmaceutical Co., Ltd.China Company GMP cert on recordActive DMF 44386 · latest filing Sept 2026
- Zhejiang Tasln Biopharma Co., Ltd.ChinaActive DMF 43241 · latest filing Jul 2026
- ZHEJIANG ZERUI BIOPHARMA CO LTDChinaActive DMF 40471 · latest filing Dec 2024
- ZYDUS WORLDWIDE DMCCActive DMF 36389 · latest filing Oct 2021
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (28 listed products contain Semaglutide). The latest listed patent expires 17 Feb 2041. The latest listed exclusivity runs to 19 Mar 2029. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Overview
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the management of type 2 diabetes and chronic weight management. It stimulates insulin secretion and signals to the brain to reduce appetite and caloric intake.
Chemical identity
- IUPAC name
- 18-[[(1R)-4-[2-[2-[2-[2-[2-[2-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-2-methylpropanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-18-oxooctadecanoic acid
- Canonical SMILES
- CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC6=CN=CN6)N
- InChIKey
- DLSWIYLPEUIQAV-CCUURXOWSA-N
- Synonyms
- cagrisema component semaglutide, nn-9535, nn1535 icosema component semaglutide, nn1535 laisema component semaglutide, nn9535, nnc 0113-0217, nnc-0113-0217, ozempic, rybelsus, wegovy
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- GLP-1 Receptor Agonist
- Mechanism of action
- Glucagon-like Peptide-1 (GLP-1) Agonists
- Chemical structure
- Glucagon-Like Peptide 1
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Semaglutide?
61 organisations hold an active US FDA Type II Drug Master File or a CEP for Semaglutide: FUJIAN GENOHOPE BIOTECH LTD (China), SHENZHEN JYMED TECHNOLOGY CO LTD (China), ZHEJIANG PEPTITES BIOTECH CO LTD (China), Hybio Pharmaceutical Co., Ltd. (China), SINOPEP-ALLSINO BIOPHARMACEUTICAL CO LTD (China), Polypeptide (Belgium), Yangzhou Aurisco Pharmaceutical Co.,Ltd. (China) and ALP PHARM BEIJING CO LTD, and 53 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Semaglutide Drug Master Files are active?
FUJIAN GENOHOPE BIOTECH LTD (DMF 39522, 40957), SHENZHEN JYMED TECHNOLOGY CO LTD (DMF 41170, 36009), ZHEJIANG PEPTITES BIOTECH CO LTD (DMF 42288, 35712), Hybio Pharmaceutical Co., Ltd. (DMF 44328, 40319), SINOPEP-ALLSINO BIOPHARMACEUTICAL CO LTD (DMF 43275, 42796), Polypeptide (DMF 36101, 38177), Yangzhou Aurisco Pharmaceutical Co.,Ltd. (DMF 38479, 42525) and ALP PHARM BEIJING CO LTD (DMF 35875) and 53 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
Does the FDA Orange Book list patents for products containing Semaglutide?
Yes. The latest patent listed for an approved US product containing Semaglutide expires 17 Feb 2041, across 28 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Semaglutide supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Semaglutide?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.